Do you know their travel plans ? Help keep them covered from Hep A to B 1 , 2
combined hepatitis A and hepatitis B vaccine
Do you know their travel plans ? Help keep them covered from Hep A to B 1 , 2
Travelling to hepatitis A and B endemic countries can put your patients aged 40 and over at risk of hepatitis A and B infection * 2-4
* Individuals aged ≥40 years may be less likely to have previously received hepatitis B vaccine . Funded hepatitis B programs have included the national infant program which commenced in 2000 , and various adolescent programs from 1996-2013 . 5
Twinrix ( 720 / 20 ) The only combination Hep A & B vaccine for Aussie travellers † 1 , 2
Vaccination schedule for individuals aged ≥16 years ‡ 1 Standard Schedule
Day 0 Month 1 Month 6
Rapid Schedule § for use in exceptional circumstances where rapid protection is required
Day 0 Day 7 Day 21 Month 12
†
Twinrix ( 720 / 20 ) is not exclusive to travellers ; it is a vaccine available for all eligible patients in Australia . ‡ For paedriatric and other dosing schedule please see the Full Product Information .
§
When this rapid schedule is used , a fourth dose is recommended 12 months after the first dose , as lower seroprotection rates against hepatitis B were observed after the third dose as compared to the standard 0 , 1 , 6 month schedule . For elderly subjects , patients on haemodialysis , and persons with an impaired immune system , refer to the Product Information . The rapid schedule has not been studied and is not recommended in such patients . 1
Twinrix ( 720 / 20 ) should be administered intramuscularly into the deltoid region of the upper arm in adults and older children . Twinrix ( 720 / 20 ) should never be administered intravenously . 1
Vaccinate appropriate travelling patients with Twinrix ( 720 / 20 ) to help protect them against hepatitis A & B † 1
†
Twinrix ( 720 / 20 ) is not exclusive to travellers ; it is a vaccine available for all eligible patients in Australia .
Twinrix ( 720 / 20 ) is indicated for active immunisation against hepatitis A and B virus infection in individuals from 1 year of age . 1 In pivotal trials of Twinrix ( 720 / 20 ) the most common adverse effects were pain , redness and swelling at the injection site , fatigue , headache , gastrointestinal symptoms ( such as diarrhoea , nausea , vomiting ), malaise and viral infection . 1
PBS Information : This product is not listed on the National Immunisation Program ( NIP ) or the PBS .
Please review full Product Information before prescribing . Product Information can be accessed at gsk . com . au / twinrix or by scanning the QR code .
Hep , hepatitis . References : 1 . Twinrix ( 720 / 20 ) Product Information . 2 . Australian Technical Advisory Group on Immunisation ( ATAGI ). Australian Immunisation Handbook . Australian Government Department of Health , Canberra , 2023 . Available at https :// immunisationhandbook . health . gov . au ( Accessed March 2024 ). 3 . Centres for Disease Control and Prevention ( CDC ). Hepatitis A . The Yellow Book 2024 , Section 5 ( 28 ). Available at : https :// wwwnc . cdc . gov / travel / yellowbook / 2024 / infections-diseases / hepatitis-a ( Accessed March 2024 ). 4 . Centres for Disease Control and Prevention ( CDC ). Hepatitis B . The Yellow Book 2024 , Section 5 ( 28 ). Available at : https :// wwwnc . cdc . gov / travel / yellowbook / 2024 / infections-diseases / hepatitis-b ( Accessed March 2024 ). 5 . National Centre for Immunisation Research and Surveillance ( NCIRS ). History of immunisation in Australia . Hepatitis B . Available at : https :// ncirs . org . au / sites / default / files / 2022-11 / Hepatitis-B-history-November % 202022 . pdf ( Accessed March 2024 ).
For information on GSK products or to report an adverse event involving a GSK product , please contact GSK Medical Information on 1800 033 109 . GlaxoSmithKline Australia Ply Ltd . ABN 47 100 162 481 . Melbourne , VIC . Trademarks are owned by or licensed to the GSK group of companies . © 2024 GSK group of companies or its licensor . PM-AU-TVX-ADVR-240001 . Date of Approval : November 2024 .